Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma
Mertens, Jorre S; van den Reek, Juul M; Kievit, Wietske; van de Kerkhof, Peter C M; Thurlings, Rogier M; Radstake, Tim R D; Seyger, Marieke M B; de Jong, Elke M G J
(2016) Acta Dermato-Venereologica, volume 96, issue 7, pp. 943 - 947
(Article)
Abstract
Data regarding the efficacy and safety of methotrexate (MTX) in adults with localized scleroderma (LoS) is scarce. This study gathered data from a retrospective cohort of adult patients with LoS (n?=?107), treated with MTX (1993-2015). MTX drug survival and predictors thereof were analysed. After 1 and 2 years, 26% and
... read more
63% of patients stopped MTX due to disease remission, respectively. Patients with younger age at MTX initiation (hazard ratio (HR) 1.159 (95% confidence interval (CI) 1.052-1.277)) and those with no other autoimmune diseases (HR 3.268 (95% CI 1.334-8.009)) more often stopped MTX due to disease remission. In addition, 24% of patients stopped MTX due to treatment failure within one year. Patients with circumscribed superficial LoS (HR 0.221 (95% CI 0.081-0.601)) experienced treatment failure less often than those with other LoS subtypes. Finally, adding folic acid (HR 0.184 (95% CI 0.079-0.425)) and reducing treatment delay (HR 1.056 (95% CI 1.004-1.112)) could be the most important factors in minimizing MTX treatment failure in LoS in clinical practice.
show less
Download/Full Text
Not available. The author may have various reasons for not providing access, for instance because it is prohibited by the commissioner of the research, or because the author is conducting further research on the subject.
Keywords: Adolescent, Adult, Aged, Antirheumatic Agents, Child, Child, Preschool, Female, Folic Acid, Humans, Infant, Male, Methotrexate, Middle Aged, Remission Induction, Retrospective Studies, Scleroderma, Localized, Treatment Outcome, Journal Article, Journal Article
ISSN: 0001-5555
Publisher: Society for the Publication of Acta Dermato-Venereologica
(Publisher version, Peer reviewed)